Targets › IKZF3
3 programs from 3 companies in 13 trials: 6 Phase 1, 5 Phase 2, 2 Phase 3; Oncology, Immunology; next expected readout Dec 2026.
Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. (UniProt, Q9UKT9)
Open in Phaseline: the race on IKZF3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Golcadomide (CC-99282, BMS-986369) Cereblon E3 ligase modulator; dual IKZF1/IKZF3 degrader | CRBN, IKZF1, IKZF3 | Phase 3 | Large B-cell Lymphoma; Follicular Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin … | Apr 2027 |
| Q32 Bio | bempikibart (ADX-914) IKZF3 degrader (molecular glue) | IKZF3 | Phase 2 | Atopic Dermatitis; Alopecia Areata | – |
| Abdullah Khan | CC-92480 IKZF1/IKZF3 degrader | IKZF1, IKZF3 | Phase 1 | Recurrent Multiple Myeloma | Dec 2026 |
Large B-cell Lymphoma (1) Follicular Lymphoma (1) Lymphoma, Follicular (1) Lymphoma, Non-Hodgkin (1) Lymphoma, B-Cell (1) Diffuse Large B-cell Lymphoma Refractory (1) Follicular Lymphoma Stage II (1) B-Cell Non-Hodgkin Lymphoma-Recurrent (1) Peripheral T Cells Lymphoma (PTCL) (1) Recurrent Mantle Cell Lymphoma (1) Atopic Dermatitis (1) Alopecia Areata (1)
mixed (2), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.